Catalyst Biosciences Announces Multiple Presentations at the Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis
Conference call and webcast to be held Wednesday, July 18, 2018 at 8:30 a.m. EDT
SOUTH SAN FRANCISCO, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the presentation of two posters at the 64th Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH) being held in Dublin on July 18-21, 2018.
The posters, presented by Dr. Howard Levy, chief medical officer of Catalyst, entitled: “Phase 2 Trial of Subcutaneously Administered Novel FVIIa Variant, Marzeptacog alfa (activated), in Hemophilia A or B with Inhibitors: Pharmacokinetics, Pharmacodynamics, Safety and Efficacy” and “Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Safety,” will discuss the current clinical data from Catalyst’s hemophilia programs.
Dr. Levy said, “We look forward to sharing interim data from our Factor VIIa program demonstrating the efficacy of subcutaneously (SQ) administered marzeptacog alfa (activated) for the treatment of hemophilia A or B with inhibitors. We will also provide an update on our SQ Factor IX CB 2679d program for the treatment of hemophilia B.”
| Poster presentations | ||
| Presentation Title: | Phase 2 Trial of Subcutaneously Administered Novel FVIIa Variant, Marzeptacog alfa (activated), in Hemophilia A or B with Inhibitors: Pharmacokinetics, Pharmacodynamics, Safety and Efficacy | |
| Presenter: | Howard Levy, M.B.B.Ch., Ph.D., M.M.M. | |
| Abstract Number: | PB196 | |
| Session: | Poster Session #1 | |
| Date/Time: | Wednesday, July 18, 2018 from 5:00-6:30 p.m. IST | |
| Presentation Title: | Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Safety | |
| Presenter: | Howard Levy, M.B.B.Ch., Ph.D., M.M.M. | |
| Abstract Number: | PB159 | |
| Session: | Poster Session #1 | |
| Date/Time: | Wednesday, July 18, 2018 from 5:00-6:30 p.m. IST | |
A copy of the presentation materials can be accessed on the section of the Catalyst website once the presentations conclude.
Conference Call Details
The management team will host a conference call for investors on Wednesday July 18, 2018, at 8:30 a.m. EDT to discuss the Factor VIIa and Factor IX clinical data. Conference call, webcast and post-conference call replay details are as follows:
Domestic: +1.877.425.9470
International: +1.201.389.0878
Conference ID: 13681615
Webcast:
A replay will be available two hours after completion of the call through August 1, 2018:
Domestic: +1.844.512.2921
International: +1.412.317.6671
Replay ID: 13681615
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit .
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical fact, included in this press release regarding our strategy, the efficacy of subcutaneously administered marzeptacog alfa (activated), potential uses and benefits of CB 2679d and marzeptacog alfa (activated), and development plans for these product candidates are forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements as a result of various important factors, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that ongoing or future trials will not replicate the results from earlier human trials or from prior animal studies, that potential adverse effects may arise from the testing or use of the Company’s products, including the generation of antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 19, 2018, along with our other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Contacts
Investors:
Fletcher Payne, CFO
Catalyst Biosciences, Inc.
+1.650.871.0761
Media:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
+1.646.751.4361
